Biotech Values

[Stop at 2]

> "biogen that's slowing it down on purpose."


Not sure how quickly Biogen is following thru, but here's an excerpt from a Leman Brothers report dated 4/17/07:

Tysabri remains the most important focus for BIIB, and with FDA accepting the Crohn’s Disease filing, the possibility of a CD approval before year-end could lead to upside in 2008. Furthermore, a recently initiated plasma exchange study and the Alnylam RNAi initiative signify BIIB’s commitment to generate data to assist the management of the likely cases of PML that could begin to crop up by year-end. In MS, BIIB will initiate head-to-head studies of Tysabri and other first-line MS agents, in addition to exploring opportunities beyond oncology. Recall that Tysabri did not work in Rheumatoid Arthritis.